Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 1/20 | 0.47 |
| ▸ | RORC | P51449 | 8/20 | 0.44 |
| ▸ | ACLY | P53396 | 2/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | APAF1 | O14727 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29297726 | 0.87 | THRB (0.43) | VCAM1ACLYSLC22A12PTGDR2ALDH1A1 | |
| SCHEMBL29297728 | 0.83 | VCAM1 (0.42) | VCAM1RORCACLYSLC22A12PTGDR2 | |
| SCHEMBL4195364 | 0.82 | EPAS1 (0.51) | VCAM1ACLYSLC22A12PTGDR2ALDH1A1 | |
| SCHEMBL15867027 | 0.82 | VCAM1 (0.53) | VCAM1ACLYSLC22A12PTGDR2ALDH1A1 | |
| SCHEMBL30863565 | 0.81 | PTGDR2 (0.45) | RORCPTGDR2GAAALDH1A1MAPT | |
| SCHEMBL15806065 | 0.81 | PTGDR2 (0.45) | RORCPTGDR2GAAALDH1A1MAPT | |
| SCHEMBL1939729 | 0.80 | VCAM1 (0.51) | VCAM1ACLYSLC22A12PTGDR2ALDH1A1 | |
| SCHEMBL15794073 | 0.79 | GAA (0.39) | RORCPTGDR2GAAALDH1A1 | |
| SCHEMBL3246788 | 0.79 | GABRA2 (0.45) | RORCACLYSLC22A12PTGDR2GAA | |
| SCHEMBL13601374 | 0.77 | MAPK1 (0.48) | PTGDR2GAAALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765768-B1 | SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2013-11-06 | — | — | EP | disclosed |
| CN-101326161-B | Novel compounds | ASTRAZENECA AB | 2013-04-17 | — | — | CN | disclosed |
| CN-102557971-A | Substituted acids for the treatment of respiratory diseases | ASTRAZENECA AB | 2012-07-11 | — | — | CN | disclosed |
| CN-101014564-B | Substituted acids for the treatment of respiratory diseases | ASTRAZENECA AB | 2012-05-09 | — | — | CN | disclosed |
| US-8022248-B2 | 3-[2-(3-Cyanophenoxy)-4-(trifluoromethyl)phenyl]propanoic acid;prostaglandin D2 inhibitor, orphan receptor CRTH2 antagonist; antiinflammatory, analgesic, antipyretic; respiratory system disorders: asthma and rhinitis; coupling amino/thio-phenyl derivatives with ester followed by hydrolysis to acid | ASTRAZENECA AB (SE) | 2011-09-20 | — | — | US | disclosed |
| US-20090192163-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| CN-101326161-A | Novel compounds | ASTRAZENECA AB (SE) | 2008-12-17 | — | — | CN | disclosed |
| EP-1937632-A1 | NOVEL COMPOUNDS | Astra Zeneca AB (SE) | 2008-07-02 | — | — | EP | disclosed |
| US-20080114002-A1 | Substituted Acids for the Treatment of Respiratory Diseases | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | US | disclosed |
| CN-101014564-A | Substituted acids for the treatment of respiratory diseases | ASTRAZENECA AB (SE) | 2007-08-08 | — | — | CN | disclosed |
| WO-2007039736-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
| EP-1765768-A1 | SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES | AstraZeneca AB (SE) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006005909-A1 | SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114002-A1 | Substituted Acids for the Treatment of Respiratory Diseases | HRH2, HRH1, HRH4 | VCAM1 4075/4885RORC 58/4885ACLY 309/4885 |
| US-20090192163-A1 | Novel Compounds | PAH, PC, DDC | VCAM1 3354/4885RORC 328/4885ACLY 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.